AOD-9604 Side Effects: Human Studies and Safety Gaps

AOD-9604 has published human safety data. A 2013 report summarizes six historical intravenous or oral trials. The important question is what those studies can tell us about reported adverse events, and where their findings stop. They do not establish the safety of a different preparation injected under the skin.

Correction (13 October 2026): an earlier version of this article incorrectly said no human safety trial had been published. This revision replaces that premise with the historical trial record and the limitations in FDA’s 2024 assessment.

What was actually studied

Stier, Vos and Kenley describe six randomized, double-blind, placebo-controlled studies. Two used single intravenous doses; four used oral products, with treatment lasting from a single exposure to 24 weeks. All six were run by the developer, Metabolic Pharmaceuticals, and the authors disclose employment or consulting ties to the company. These are summaries of historical studies, not six independent modern trials of clinic injections.

Historical trials described in the 2013 report

Reported study populations include placebo participants. Counts are not the number of people exposed to AOD-9604 alone, and cannot be pooled into a side-effect rate. Sources: the 2013 report/supplement and FDA’s 2024 assessment.

Which adverse events were reported?

An adverse event is something recorded during a study; it is not automatically caused by the study drug. Severity describes intensity, while “serious” is a separate trial classification. FDA’s detailed safety assessment helps distinguish the route, trial and investigator attribution.

In METAOD002, 23 men received AOD-9604 and placebo in separate intravenous treatment periods. Headache was reported by 16 participants across the study, which is not an AOD-only incidence. One severe chest-tightness event during an active period was judged possibly related. Euphoria was reported by five participants during active periods and none during placebo periods, also judged possibly related. No serious adverse events were reported in this small IV study.

For oral treatment, FDA describes headache, diarrhea and flatulence among reported events. In METAOD003, a diarrhea event was classified as serious and possibly related to treatment; a pneumonia event was considered unrelated. In the seven-day METAOD004 study, the highest tested oral-dose group had more headaches, diarrhea and flatulence. These summaries do not supply a dependable risk percentage for a different product or route.

In the 12-week METAOD005 study, five participants reported serious adverse events, including several cancers and a lipoma. The investigators considered them unrelated to treatment. FDA later found the available details insufficient to assess that conclusion, particularly for the cancers. The record does not establish that AOD-9604 caused cancer, or exclude that possibility.

In the 24-week study, the publisher’s Table 2 lists 18 participants with at least one serious adverse event: eight in placebo and ten across the three active arms. These are participant counts, not counts of individual events, and the active groups together contained more people than placebo. The table cannot establish equivalence or long-term safety.

Why the favorable safety conclusion has limits

The 2013 authors reached a favorable tolerability conclusion. FDA’s 2024 review identifies missing event-level detail, incomplete intervention and outcome reporting, and short study durations. Its surveillance reviewers could not identify a safety signal from these limited summaries; that is not proof of no risk. Investigator judgments of relatedness and a regulator’s ability to assess those judgments are different things.

The report also describes no statistically significant IGF-1 differences versus placebo and no detected anti-AOD-9604 antibodies in the selected patients tested. Those measured findings cannot establish absence of every endocrine, immune or long-term harm. A negative antibody test in a subset receiving historical oral products does not settle the immunogenicity of a subcutaneous preparation.

A 2026 review of peptides sold outside regulated channels, AOD-9604 among them, reached a similar view: rigorous human safety data for these compounds are scarce.^[1]

What this means for subcutaneous products

In its 2024 assessment, FDA did not identify human exposure data for the proposed subcutaneous or transdermal routes. The submitted clinical reports did not consistently identify whether the material was free base or an acetate salt. FDA also identified gaps in pharmacokinetic and bioavailability information, and concerns about peptide impurities, aggregation and immunogenicity. These are dated findings, not a claim that every study published since then has been searched.

A historical controlled-study product is not interchangeable with a clinic mixture or a vial bought online. Route, formulation, manufacturing and storage matter when judging applicability. This article does not verify an individual seller, lot, compounded product or combination regimen, and it does not provide a dose or injection protocol.

Safety reporting also does not establish weight-loss benefit

FDA’s separate effectiveness review describes the larger oral OPTIONS trial as failing to demonstrate a statistically significant weight-loss difference versus placebo. Its efficacy account relies on limited reports and a developer filing, rather than a complete published efficacy report. The historical safety paper cannot be used as proof that a current weight-loss program works.

What would make the answer more useful?

For the actual route and preparation under consideration, a useful safety report would identify exposed and comparison groups, follow-up, withdrawals, event definitions and individual-event details. It would separate recorded events from causal assessments and explain missing data. The existing human record deserves accurate description without converting its reporting gaps into a product guarantee.

For a practical way to inspect what a certificate of analysis does and does not show, use the existing COA worksheet. It supports document reading; it does not certify clinical safety. Research updates are available through the existing newsletter signup.

Sources and review scope

Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (2013), DOI 10.4021/jem157w. Full report, Tables 1–2 and linked trial-summary supplement. The trials were run by the developer, Metabolic Pharmaceuticals; the authors disclose employment or consulting ties to it.

FDA briefing for the December 4, 2024 Pharmacy Compounding Advisory Committee meeting: effectiveness pages 21–23 and human-safety pages 32–38 (printed page numbers). This article reports that historical assessment; it is not a current legal or approval determination.

This is a source-existence and evidence-scope correction, not an exhaustive systematic review, independent patient-level reanalysis or completed clinical review. Earlier animal and class-wide comparisons have been removed from this safety answer because they cannot replace route-specific human data.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.